A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
Alzforum,
Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P, REVERSE-SD Study Investigators.